<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20241031//EN"
        "https://jats.nlm.nih.gov/publishing/1.4/JATS-journalpublishing1-4.dtd">
<article  article-type="research-article"        dtd-version="1.4">
            <front>

                <journal-meta>
                                                                <journal-id>j. res. pharm.</journal-id>
            <journal-title-group>
                                                                                    <journal-title>Journal of Research in Pharmacy</journal-title>
            </journal-title-group>
                                        <issn pub-type="epub">2630-6344</issn>
                                                                                            <publisher>
                    <publisher-name>Marmara University</publisher-name>
                </publisher>
                    </journal-meta>
                <article-meta>
                                        <article-id pub-id-type="doi">10.29228/jrp.25</article-id>
                                                                <article-categories>
                                            <subj-group  xml:lang="en">
                                                            <subject>Basic Pharmacology</subject>
                                                            <subject>Medical Pharmacology</subject>
                                                    </subj-group>
                                            <subj-group  xml:lang="tr">
                                                            <subject>Temel Farmakoloji</subject>
                                                            <subject>Tıbbi Farmakoloji</subject>
                                                    </subj-group>
                                    </article-categories>
                                                                                                                                                        <title-group>
                                                                                                                                                            <article-title>Higher alpha-synuclein aggregate density does not lead to more severe dopaminergic cell loss in the AAV-mediated overexpression model of Parkinson’s Disease: A time- course study</article-title>
                                                                                                    </title-group>
            
                                                    <contrib-group content-type="authors">
                                                                        <contrib contrib-type="author">
                                                                <name>
                                    <surname>Tel</surname>
                                    <given-names>Banu Cahide</given-names>
                                </name>
                                                                    <aff>Department of Pharmacology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                <name>
                                    <surname>Kazkayası</surname>
                                    <given-names>Inci</given-names>
                                </name>
                                                                    <aff>Department of Pharmacology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                <name>
                                    <surname>Telli</surname>
                                    <given-names>Gökçen</given-names>
                                </name>
                                                                    <aff>Department of Pharmacology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                <name>
                                    <surname>Çinar</surname>
                                    <given-names>Elif</given-names>
                                </name>
                                                                    <aff>Department of Pharmacology, Faculty of Pharmacy, Zonguldak Bülent Ecevit University, Zonguldak, Turkey.</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                <name>
                                    <surname>Mutluay</surname>
                                    <given-names>Sevgi Uğur</given-names>
                                </name>
                                                                    <aff>Department of Pharmacology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                <name>
                                    <surname>Yalçin-çakmakli</surname>
                                    <given-names>Gül</given-names>
                                </name>
                                                                    <aff>Department of Neurology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                <name>
                                    <surname>Saka</surname>
                                    <given-names>Esen</given-names>
                                </name>
                                                                    <aff>Department of Neurology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                <name>
                                    <surname>Elibol</surname>
                                    <given-names>Bülent</given-names>
                                </name>
                                                                    <aff>Department of Neurology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.</aff>
                                                            </contrib>
                                                                                </contrib-group>
                        
                                        <pub-date pub-type="pub" iso-8601-date="20250627">
                    <day>06</day>
                    <month>27</month>
                    <year>2025</year>
                </pub-date>
                                        <volume>25</volume>
                                        <issue>3</issue>
                                        <fpage>352</fpage>
                                        <lpage>358</lpage>
                        
                        <history>
                                    <date date-type="received" iso-8601-date="20210325">
                        <day>03</day>
                        <month>25</month>
                        <year>2021</year>
                    </date>
                                                    <date date-type="accepted" iso-8601-date="20210507">
                        <day>05</day>
                        <month>07</month>
                        <year>2021</year>
                    </date>
                            </history>
                                        <permissions>
                    <copyright-statement>Copyright © 2010, Journal of Research in Pharmacy</copyright-statement>
                    <copyright-year>2010</copyright-year>
                    <copyright-holder>Journal of Research in Pharmacy</copyright-holder>
                </permissions>
            
                                                                                                                        <abstract><p>Pathological intracellular aggregation of alpha-synuclein (a-syn) is the hallmark of Parkinson’s disease (PD). Our aim is to explore the outcomes of long-term a-syn pathology with its functional correlates in the PD model by AAV (adeno-associated virus)-mediated a-syn overexpression in substantia nigra (SN). Female Wistar rats (220-260 g) received a unilateral injection of AAV-human-a-syn or green fluorescent protein (GFP) gene into the SN. The animals were tested for motor functions with cylinder test at 8, 12 weeks or 9 months post-injection. The intensity of a-syn accumulation or GFP in striatum and dopaminergic neuronal loss in SN, dopaminergic terminal loss in striatum and synaptic integrity were analyzed by a-syn, GFP, tyrosine hydroxylase (TH) and synaptophsin immunohistochemistry, respectively. At all time-points, AAV-human-a-syn injected animals displayed more motor dysfunction and TH- positive cell loss compared to AAV-GFP injected group. A-syn immunoreactivity was present in the nigral neurons as well as the striatal terminals in all animals that received AAV-a-syn. Striatal TH density analysis showed a decrease in both 12-weeks and 9 months a-syn groups compared to controls. However, TH-positive neuron count was lower in 9- months group compared to 12-weeks group. Hence, the motor performance of 9-month group showed an improvement which may be a sign of a compensatory mechanisms against a-syn-induced neurodegeneration. The findings of this study implicate that higher a-syn density in SN does not always lead to worse motor function or more severe dopaminergic cell loss. This may support the hypothesis that a-syn aggregates are the end-product of a cellular defense mechanism rather than being causative pathology.</p></abstract>
                                                            
            
                                                                                        <kwd-group>
                                                    <kwd>Alpha-synuclein</kwd>
                                                    <kwd>  Parkinson’s disease</kwd>
                                                    <kwd>  adeno associated viral vectors</kwd>
                                                    <kwd>  animal model.</kwd>
                                            </kwd-group>
                            
                                                                                                                                                    </article-meta>
    </front>
    <back>
                            <ref-list>
                                    <ref id="ref1">
                        <label>1</label>
                        <mixed-citation publication-type="journal">[1] Chartier S, Duyckaerts C. Is Lewy pathology in the human nervous system chiefly an indicator of neuronal protection or of toxicity? Cell Tissue Res. 2018; 373(1): 149-60. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref2">
                        <label>2</label>
                        <mixed-citation publication-type="journal">[2] Titova N, Schapira AHV, Chaudhuri KR, Qamar MA, Katunina E, Jenner P. Nonmotor Symptoms in Experimental Models of Parkinson&#039;s Disease. Int Rev Neurobiol. 2017; 133: 63-89. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref3">
                        <label>3</label>
                        <mixed-citation publication-type="journal">[3] Chiu WH, Depboylu C, Hermanns G, Maurer L, Windolph A, Oertel WH, Ries V, Höglinger GU. Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson&#039;s disease. Neuropharm. 2015; 95: 367-76. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref4">
                        <label>4</label>
                        <mixed-citation publication-type="journal">[4] Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci. 2002; 22(7): 2780-91. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref5">
                        <label>5</label>
                        <mixed-citation publication-type="journal">[5] Decressac M, Mattsson B, Lundblad M, Weikop P, Bjorklund A. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons. Neurobiol Dis. 2012; 45(3): 939-53. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref6">
                        <label>6</label>
                        <mixed-citation publication-type="journal">[6] Gombash SE, Manfredsson FP, Kemp CJ, Kuhn NC, Fleming SM, Egan AE, et al. Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system. PLoS One. 2013; 8(11): e81426. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref7">
                        <label>7</label>
                        <mixed-citation publication-type="journal">[7] Oliveras-Salva M, Van der Perren A, Casadei N, Stroobants S, Nuber S, D&#039;Hooge R, et al. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration. Mol Neurodegener. 2013; 8: 44. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref8">
                        <label>8</label>
                        <mixed-citation publication-type="journal">[8] Van der Perren A, Van den Haute C, Baekelandt V. Viral vector-based models of Parkinson&#039;s disease. Curr Top Behav Neurosci. 2015; 22: 271-301. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref9">
                        <label>9</label>
                        <mixed-citation publication-type="journal">[9] Bourdenx M, Dovero S, Engeln M, Bido S, Bastide MF, Dutheil N, et al. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by alpha-synuclein overexpression. Acta Neuropathol Commun. 2015; 3: 46. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref10">
                        <label>10</label>
                        <mixed-citation publication-type="journal">[10] Ulusoy A, Decressac M, Kirik D, Bjorklund A. Viral vector-mediated overexpression of alpha-synuclein as a progressive model of Parkinson&#039;s disease. Prog Brain Res. 2010; 184: 89-111. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref11">
                        <label>11</label>
                        <mixed-citation publication-type="journal">[11] Mutluay SU, Çınar E, Yalçın Çakmaklı G, Ulusoy A, Elibol B, Tel BC. Modelling Non-motor Symptoms of Parkinson’s Disease: AAV Mediated Overexpression of Alpha-synuclein in Rat Hippocampus and Basal Ganglia. Turk J Neurol. 2020; 26(4): 322-329. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref12">
                        <label>12</label>
                        <mixed-citation publication-type="journal">[12] Albert K, Voutilainen MH, Domanskyi A, Airavaara M. AAV Vector-Mediated Gene Delivery to Substantia Nigra Dopamine Neurons: Implications for Gene Therapy and Disease Models. Genes (Basel). 2017; 8(2): 63. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref13">
                        <label>13</label>
                        <mixed-citation publication-type="journal">[13] Koprich JB, Johnston TH, Huot P, Reyes MG, Espinosa M, Brotchie JM. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson&#039;s disease produced by decreasing doses of alpha-synuclein. PLoS One. 2011; 6(3): e17698. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref14">
                        <label>14</label>
                        <mixed-citation publication-type="journal">[14] Landeck N, Buck K, Kirik D. Toxic effects of human and rodent variants of alpha-synuclein in vivo. Eur J Neurosci. 2017; 45(4): 536-547. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref15">
                        <label>15</label>
                        <mixed-citation publication-type="journal">[15] Cinar E, Yalcin-Cakmakli G, Saka E, Ulusoy A, Yuruker S, Elibol B, et al. Modelling cognitive deficits in Parkinson&#039;s disease: Is CA2 a gateway for hippocampal synucleinopathy? Exp Neurol. 2020; 330: 113357. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref16">
                        <label>16</label>
                        <mixed-citation publication-type="journal">[16] Albert K, Voutilainen MH, Domanskyi A, Piepponen TP, Ahola S, Tuominen RK, et al. Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson&#039;s disease. J Neurosci Res. 2019; 97(3): 346-61. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref17">
                        <label>17</label>
                        <mixed-citation publication-type="journal">[17] Delenclos M, Faroqi AH, Yue M, Kurti A, Castanedes-Casey M, Rousseau L, et al. Neonatal AAV delivery of alpha-synuclein induces pathology in the adult mouse brain. Acta Neuropathol Commun. 2017; 5(1): 51. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref18">
                        <label>18</label>
                        <mixed-citation publication-type="journal">[18] Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T, Muzyczka N, Mandel RJ, et al. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain. 2007; 130(Pt 3): 799-815. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref19">
                        <label>19</label>
                        <mixed-citation publication-type="journal">[19] Paxinos G WC. The Rat Brain in Stereotaxic Coordinates: Hard Cover Edition: AcademicPress; 2006.</mixed-citation>
                    </ref>
                                    <ref id="ref20">
                        <label>20</label>
                        <mixed-citation publication-type="journal">[20] Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012; 9(7):671-5. [CrossRef] [3] Chiu WH, Depboylu C, Hermanns G, Maurer L, Windolph A, Oertel WH, Ries V, Höglinger GU. Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson&#039;s disease. Neuropharm. 2015; 95: 367-76. [CrossRef]</mixed-citation>
                    </ref>
                            </ref-list>
                    </back>
    </article>
